Browse studies
Find your next paid study
2 recruiting studies matching your filters
Phase 1
A Phase I/II, Open-label, Multicenter Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of Anti-GPRC5D CAR-T Cell Product (OriCAR-017) in Subjects With Relapsed/Refractory Multiple Myeloma.
The is a first clinical study for Oricell Therapeutics Inc. in the United States to evaluate the safety, PK, PD and preliminary efficacy of our anti-GPRC5D cel…
Neoplasms, Plasma CellNeoplasms by Histologic TypeNeoplasms+11 more
OriCell Therapeutics Co., Ltd.NCT06271252
Phase 1
A Phase 1 Study to Evaluate the Safety of KLN-1010, a Novel, In Vivo Gene Therapy to Generate Anti-B Cell Maturation Antigen (Anti-BCMA) Chimeric Antigen Receptor-T Cells (CAR-T) in Patients With Relapsed and Refractory Multiple Myeloma
The goal of this clinical trial is to evaluate the safety, tolerability, and recommended Phase 2 Dose (RP2D) of KLN-1010 in patients with relapsed or refractor…
Multiple Myeloma in RelapseMyeloma MultipleMultiple Myeloma Progression+11 more
Kelonia Therapeutics, Inc.NCT07075185